Jordan Feld
University of Toronto · University Health Network, Toronto · University Health Network / Toronto Centre for Liver Disease
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jordan Feld as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:45 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07237282 · A Phase 1 Clinical Trial of Adjuvanted Protein-based HCV Vaccine Candidates (HCV Vaccine Trial)University of Alberta · not yet recruiting · Hepatitis C · principal investigator
- Ph2NCT06216470 · Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]University Health Network, Toronto · recruiting · Hepatitis B, Chronic · principal investigator
- Ph3NCT04967430 · TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19University Health Network, Toronto · unknown · Sars-CoV2, Covid19 · principal investigator
- Ph2NCT04354259 · Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19University Health Network, Toronto · completed · Sars-CoV2, Covid-19 · principal investigator
- Ph1/Ph2NCT04046107 · Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral TherapyNational Institute of Allergy and Infectious Diseases (NIAID) · withdrawn · Hepatitis B Virus · study chair
- Ph3NCT04017338 · Transplantation Using Hepatitis C Positive Donors, A Safety TrialJordan Feld · unknown · Lung Transplant Infection, Heart Transplant Infection, Kidney Transplant Infection · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:45 UTC. The ranking covers the 200 most relevant of 61 PubMed records, and a shared surname and initials can bring in a namesake. All 61 on PubMed
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.N Engl J Med · 2015903 citationsRCR 33.5
- Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.N Engl J Med · 2013873 citationsRCR 31.4
- Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.N Engl J Med · 2014690 citationsRCR 25.4
- Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.N Engl J Med · 2018337 citationsRCR 15.3
- Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.Lancet Gastroenterol Hepatol · 2018258 citationsRCR 12.5
- Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.Hepatology · 2007227 citationsRCR 5.1
- Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.Aliment Pharmacol Ther · 2009226 citationsRCR 5.7
- Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.Hepatology · 2015205 citationsRCR 7.6
- Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.Lancet Respir Med · 2021200 citationsRCR 10.0
- Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.Gastroenterology · 2017184 citationsRCR 7.5